Core Viewpoint - The family doctor service teams in the Alxa League's Luanjing Tan Ecological Migration Demonstration Zone are providing essential healthcare services to vulnerable groups, particularly the elderly and chronic disease patients, ensuring they receive timely medical attention and health management as the Spring Festival approaches [1][2][3]. Group 1: Family Doctor Service Implementation - The family doctor service teams have been conducting home visits to provide healthcare, focusing on the elderly and patients with chronic conditions, ensuring they receive personalized medical attention [2][3]. - Since 2015, the service has included regular weekly visits, allowing for continuous health monitoring and timely adjustments to treatment plans [1][2]. - The service model includes a six-step process: appointment, home visit, assessment, education, record-keeping, and follow-up, ensuring comprehensive healthcare delivery [2][3]. Group 2: Resource Optimization and Collaboration - The demonstration zone has established nine family doctor teams using a "fixed + mobile" service model, covering 17 villages and 2 communities, with a commitment to weekly home visits [3]. - Collaboration with seven quality medical institutions has been initiated, allowing for expert consultations and joint treatment agreements, benefiting over 800 individuals [3]. - The effective coverage rate of family doctor contracts has reached 82.4%, with 100% service coverage for impoverished households and three key monitoring groups [3]. Group 3: Future Service Enhancements - Plans are in place to optimize the family doctor service mechanism, expand service content, and enhance the integration of medical and preventive care [4]. - Continuous training for grassroots healthcare providers and the expansion of personalized service packages are being prioritized to improve service effectiveness [4]. - The goal is to transition from mere coverage to effective healthcare delivery, ensuring quality medical resources are firmly established at the grassroots level [4].

（来源：经济参考报） 为有效破解医疗资源分配不均带来的问题，近年来各地大力推进各种形式的医疗联合体（以下简称"医 联体"）建设，不断优化医疗资源配置。同时，人工智能（AI）进入集中的技术爆发期，在医联体建设 中持续得到应用，有效助力优质医疗资源下沉、医疗机构服务水平提升和基层群众方便就医。从人员素 养、技术进步和制度完善等发展趋势看，AI将持续为医联体建设技术赋能。 医联体建设 与医联体建设几乎同步的是，AI进入集中的技术爆发期。2025年10月，国家卫生健康委办公厅、国家 发展改革委办公厅等联合印发《关于促进和规范"人工智能+医疗卫生"应用发展的实施意见》，对人工 智能在基层应用、临床诊疗、患者服务、中医药、公共卫生、科研教学、行业治理、健康产业等方面进 行了部署。借助AI技术，一些地方在医联体建设中正努力探索"上级医院+AI+基层医院"的管理机制和 业务体系。 首先，AI技术有效推进医联体诊疗一体化进程。在医联体建设实践中，一些地方通过推进AI技术应 用，探索建立从上级医院到基层医院一体化的智能诊疗体系，以有效解决医联体运行中地理跨度大、难 沟通、资源分散、基层需求强等难点。例如，有的地方建立基于AI技术 ...

针对老年群体的就医痛点，医院构建了"1+1+N"健康服务模式。"1名健康楼长+1名家庭医生+多学科团 队。"白雪飞说。来自北京通用航天医院的第一批35支服务小队覆盖云岗街道老龄化程度最高的6个社 区，团队成员包括护士、康复师、营养师、社区干部等。 （来源：经济参考报） "以前确实不踏实，'有病乱投医'。现在有了'健康楼长'，特别好……"北京丰台区云岗街道的老旧小区 里，60岁的徐阿姨坐在客厅，向记者谈起这一年来最让她安心的变化。她口中的"楼长"，正是此刻在家 中为她测量血压的通用健康公司北京通用航天医院副主任医师白雪飞。 在云岗街道——北京航天城所在地，一场关乎"老航天人"与社区长者健康福祉的深刻变革正在发生。临 近春节，记者跟随穿着"蓝马甲"的"健康楼长"叩响老旧小区内居民的家门。这背后，是一项名为"健康 云岗"的社区健康服务体系创新实践。 "我从2024年9月第一批试点就开始做'健康楼长'。"白雪飞一边整理随诊包，一边介绍。他在医院肾内 科工作了二十余年，如今工作场景延伸到了居民的客厅。"最大的转变是从'等病人来'到'送健康上 门'。"他总结道。在医院，病人常带着病痛前来；而在社区，他们的目标是"把疾病预 ...

Core Insights - The current market is not suitable for "lazy" static allocation, and while opportunities exist in 2026, the approach will be more challenging [1] - Foreign institutions are increasingly optimistic about Chinese assets, citing the complete industrial chain, strong innovation capabilities, and relatively attractive valuations [1][2] Group 1: Market Trends - Global asset allocation is shifting away from a heavy concentration on USD assets towards a more diversified approach, with China showing renewed vitality [1][2] - The intertwining of five major trends—AI, geopolitical situations, energy transition, aging population, and new finance—is reshaping global capital markets and increasing asset volatility [1] Group 2: Investment Strategies - Investors are encouraged to adopt a more proactive asset allocation strategy, with quarterly or semi-annual rebalancing proving more effective than a buy-and-hold approach in high-volatility markets [4] - The demand for global allocation among Chinese investors is rising, and foreign investment in China is also increasing due to the country's unique market characteristics and growth potential [2] Group 3: Sector Focus - The logic for Chinese equity assets is expected to shift from valuation expansion to profit-driven growth, with a focus on sectors like technology, power equipment, healthcare, and undervalued traditional industries [3] - The AI-driven technology revolution is anticipated to enhance productivity and corporate performance, particularly in sectors such as power equipment and healthcare, which are seen as having significant potential [3] Group 4: Fixed Income Strategies - In a low-interest-rate environment, traditional bond investments face challenges, prompting the need for new return sources or strategies, including short-term trading and credit exploration [4] - The "fixed income plus" strategy is highlighted as a crucial tool for balancing risk and return, with a focus on maintaining fixed income assets as a foundation while selectively increasing exposure to volatile assets [4][5]

Core Viewpoint - Southbound funds have increased their holdings in Jinxin Fertility (01951.HK), indicating growing investor interest in the company and its services in the assisted reproductive sector [1] Group 1: Shareholding Activity - On February 10, southbound funds increased their holdings by 679,000 shares of Jinxin Fertility [1] - Over the past five trading days, there have been four days of net increases in holdings, totaling 3.4365 million shares [1] - In the last 20 trading days, there were 14 days of net increases, amounting to 20.0356 million shares [1] - Currently, southbound funds hold 1.471 billion shares of Jinxin Fertility, representing 53.33% of the company's issued ordinary shares [1] Group 2: Company Overview - Jinxin Fertility Medical Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services [1] - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, and obstetrics and pediatrics medical services [1] - Jinxin Fertility operates mainly in China and the United States, also engaging in the sale of medical consumables and equipment [1]

（来源：劳动午报） 转自：劳动午报 本报讯 （记者 王路曼） 近日，密云区举办"携手同心，共赴未来"2026年优化营商环境大会，企业界代 表与相关政府部门负责人近300人齐聚一堂。大会发布《密云区优化营商环境十大行动计划》，并推 出"政策礼包"和"机遇清单"，为企业发展精准赋能。 会上发布密云区"十五五"时期发展愿景，详解未来五年发展蓝图。据了解，密云区将紧扣功能定位，争 当守好密云水库、打好生态牌、走好高质量发展之路的"三好生"，全面实施"以水润城、以水兴业、以 水富民"发展战略，以高水平保护实现高质量发展。未来五年，密云区将聚焦生态文明建设、灾后恢复 重建、培育新质生产力、农业农村现代化、优化营商环境等重点领域协同发力，把生态红利、发展潜力 转化为共赢实效。 现场同时发布密云区优化营商环境十大行动计划，聚焦政务服务、金融服务、土地供应、人才保障、法 治保障等领域。该计划包括30项务实举措。其中，企业办事无需重复提交证照材料，餐饮等高频行业审 批时限"再减半"，"办不成事"窗口兜底服务，首问负责机制坚决杜绝"拒绝式"回应，着力提升企业体验 感。"四级管家"层层联动，"企业吹哨、部门报到"和"诉求直通车"工作 ...

Group 1 - CVS Health reported a 2.6% increase in stock price following the announcement of fourth-quarter revenue and earnings per share that exceeded expectations [1] - The company reaffirmed its earnings per share guidance for 2026, projecting between $7.00 and $7.20 [1] - CVS maintained its revenue guidance of no less than $400 billion, attributed to improved profit margins at Aetna and benefits from new prescription initiatives at Caremark [1]

Core Insights - Labcorp Holdings Inc. is set to report its fourth-quarter 2025 results on February 17, with adjusted earnings of $4.18 in the last quarter, exceeding the Zacks Consensus Estimate by 1.21% [1] - The company has consistently surpassed earnings estimates over the past four quarters, with an average surprise of 2.68% [1] Q4 Estimates for Labcorp - The Zacks Consensus Estimate for Labcorp's fourth-quarter 2025 revenues is $3.55 billion, indicating a 6.6% increase from the previous year [2] - The estimated EPS for the fourth quarter is projected to improve by 15% to $3.95 [2] Estimate Revision Trend - Earnings estimates for Labcorp's fourth quarter have remained stable at $3.95 over the past 30 days [3] Factors Influencing Performance - The Diagnostics Laboratories segment is expected to maintain strong momentum due to organic growth and acquisitions, including the purchase of Incyte Diagnostics' clinical pathology business and other assets [4] - Demand for core tests in high-growth specialty areas such as oncology and women's health is anticipated to remain robust, supported by new testing capabilities [5] - The Labcorp OnDemand channel is likely to see continued strong adoption, contributing to a projected 7% year-over-year revenue increase in the Diagnostics segment [6] Biopharma Laboratory Services - The Biopharma Laboratory Services unit is expected to grow by 3.1% year-over-year, despite challenges from restructuring and delayed study starts [8][10] - The Central Laboratories component is anticipated to continue benefiting from its strength, although Early Development revenues faced impacts from previous quarter delays [9] Technological Advancements - Labcorp's increased use of science and technology, including the introduction of AI tools like Test Finder, is expected to enhance growth and operational efficiency [10] - Investments in digital and AI capabilities are aimed at improving core laboratory operations, with the Launchpad initiative targeting annual savings of $100-$125 million [11]

（文章来源：证券日报） 证券日报网讯 2月10日，三星医疗在互动平台回答投资者提问时表示，公司将于2026年4月25日披露 2025年年度报告，届时请关注公司后续公告。 ...

Group 1 - The JPM 2026 conference revealed innovative opportunities in the pharmaceutical and medical device sectors, particularly in the IO plus field where the trend of using VEGF dual antibodies in multiple indications is becoming established [1] - There is a focus on multinational corporations (MNCs) and leading biotech companies developing dual antibodies and combinations with monoclonal antibodies targeting other immune-related sites [1] - In the ADC (Antibody-Drug Conjugate) area, attention is drawn to first-in-class (FIC) products for large indications, new indications for major products, and advancements in dual toxin/new toxin ADC technologies, which are leading directions for domestic innovative drugs [1] Group 2 - The ETF Guotai (159377) tracks the innovative pharmaceutical index (399275), which has a daily price fluctuation limit of 20%, and selects listed companies engaged in biopharmaceuticals, chemical pharmaceuticals, traditional Chinese medicine, and medical services [2] - The index emphasizes the R&D investment and technological leadership of constituent companies, focusing on high-growth potential in the pharmaceutical health sector [2] - The ETF aims to reflect the overall performance of listed companies related to innovative biopharmaceuticals [2]